We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Government Contracts & Domain Expertise Strengthen Maximus
Read MoreHide Full Article
Key Takeaways
Maximus generates recurring revenues by delivering scalable government health and human services.
MMS maintains strong liquidity with a current ratio of 2.21 and consistent dividends.
Maximus faces risks from regulatory changes and its dependence on federal and state government contracts.
Maximus (MMS - Free Report) is capitalizing on its reputation as a trusted partner to governments worldwide by providing affordable, scalable health and human services. Strong shareholder-friendly policies and solid liquidity support its financial well-being.
Meanwhile, regulatory changes and heavy reliance on federal and state agreements pose significant threats to the company’s profitability, scalability and overall financial stability.
How Is MMS Faring?
Maximus, a global provider of government health and human services programs, leverages its business process management expertise to deliver cost-effective, efficient and large-scale solutions. This enables the company to generate predictable recurring revenue streams and positions it as a lucrative partner to governments. Demand for MMS’ offerings is growing, driven by expanded government social benefits and safety-net programs in response to rising living standards and complex health challenges.
MMS leverages its workforce's specialized knowledge to design, deploy and operate critical government health and human services, giving it a competitive advantage over its peers. The company consistently generates substantial cash flow from operations, driven by strong profit margins and disciplined collection cycles, enhancing its ability to adapt to unforeseen disruptions.
Maximus has demonstrated a strong commitment to its shareholders through dividend payments. It paid dividends of $68.1 million, $72.9 million and $68.7 million in fiscal 2023, 2024 and 2025, respectively. Such moves instill investor confidence in its stock and enhance shareholder value.
MMS’ current ratio (a measure of liquidity) at the end of the first quarter of fiscal 2026 was 2.21, higher than the industry’s 1.91. A current ratio of more than 1 indicates that the company is well-positioned to pay off its short-term obligations.
Image Source: Zacks Investment Research
Meanwhile, Maximus is experiencing slower growth in its core business segments due to heavy reliance on contracts from federal and state governments, especially in Medicaid and Medicare. The company’s top line and contract volume can be directly impacted by Shifts in public spending priorities.
Operating in a highly regulated industry exposes MMS to significant regulatory risks. Maximus’s ability to win contracts or sustain existing ones can be directly influenced by policy shifts or changes to government healthcare programs under different political administrations. Stricter contractor regulations could increase operational costs and reduce margins.
Veralto Corporation carries a Zacks Rank #2 at present. It has a long-term earnings growth expectation of 8.4%. VLTO delivered a trailing four-quarter earnings surprise of 4.9%, on average.
Corpay, Inc. also holds a Zacks Rank of 2 at present. It has a long-term earnings growth expectation of 14.3%. CPAY's earnings beat estimates in three of the last four reported quarters, while matching once, with the surprise being 2%, on average.
View the Zacks #1 Rank List
Image: Bigstock
Government Contracts & Domain Expertise Strengthen Maximus
Key Takeaways
Maximus (MMS - Free Report) is capitalizing on its reputation as a trusted partner to governments worldwide by providing affordable, scalable health and human services. Strong shareholder-friendly policies and solid liquidity support its financial well-being.
Meanwhile, regulatory changes and heavy reliance on federal and state agreements pose significant threats to the company’s profitability, scalability and overall financial stability.
How Is MMS Faring?
Maximus, a global provider of government health and human services programs, leverages its business process management expertise to deliver cost-effective, efficient and large-scale solutions. This enables the company to generate predictable recurring revenue streams and positions it as a lucrative partner to governments. Demand for MMS’ offerings is growing, driven by expanded government social benefits and safety-net programs in response to rising living standards and complex health challenges.
MMS leverages its workforce's specialized knowledge to design, deploy and operate critical government health and human services, giving it a competitive advantage over its peers. The company consistently generates substantial cash flow from operations, driven by strong profit margins and disciplined collection cycles, enhancing its ability to adapt to unforeseen disruptions.
Maximus has demonstrated a strong commitment to its shareholders through dividend payments. It paid dividends of $68.1 million, $72.9 million and $68.7 million in fiscal 2023, 2024 and 2025, respectively. Such moves instill investor confidence in its stock and enhance shareholder value.
MMS’ current ratio (a measure of liquidity) at the end of the first quarter of fiscal 2026 was 2.21, higher than the industry’s 1.91. A current ratio of more than 1 indicates that the company is well-positioned to pay off its short-term obligations.
Image Source: Zacks Investment Research
Meanwhile, Maximus is experiencing slower growth in its core business segments due to heavy reliance on contracts from federal and state governments, especially in Medicaid and Medicare. The company’s top line and contract volume can be directly impacted by Shifts in public spending priorities.
Operating in a highly regulated industry exposes MMS to significant regulatory risks. Maximus’s ability to win contracts or sustain existing ones can be directly influenced by policy shifts or changes to government healthcare programs under different political administrations. Stricter contractor regulations could increase operational costs and reduce margins.
Maximus currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Other Stocks to Consider
A couple of other top-ranked stocks in the broader Zacks Business Services sector are Veralto Corporation (VLTO - Free Report) and Corpay, Inc. (CPAY - Free Report) .
Veralto Corporation carries a Zacks Rank #2 at present. It has a long-term earnings growth expectation of 8.4%. VLTO delivered a trailing four-quarter earnings surprise of 4.9%, on average.
Corpay, Inc. also holds a Zacks Rank of 2 at present. It has a long-term earnings growth expectation of 14.3%. CPAY's earnings beat estimates in three of the last four reported quarters, while matching once, with the surprise being 2%, on average.